'Groundbreaking' AbbVie Suits Test Bold Anti-Generic Tactics
A trio of trailblazing antitrust lawsuits targeting AbbVie Inc. will force a day of reckoning for some of Big Pharma's most audacious and controversial maneuvers to delay generic and biosimilar competition,...To view the full article, register now.
Already a subscriber? Click here to view full article